Publications by authors named "Manon Reda"

Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2- early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this population-based study, we assess the real-life proportion, and long-term prognosis of patients treated for HR+/HER2- eBC between 2005 and 2015, and eligible for adjuvant CDK4/6 inhibitors according to these trial inclusion criteria. Among 3,103 patients, N = 440 (14.

View Article and Find Full Text PDF
Article Synopsis
  • The OlympiA study approved olaparib as an adjuvant treatment for high-risk early breast cancer patients with BRCA1/2 mutations, but the actual percentage of patients meeting these high-risk criteria in practical settings is unknown.
  • The study analyzed data from the Côte d'Or Breast and Gynecological Cancer Registry, examining the long-term prognosis of patients treated for early breast cancer between 2005 and 2015, finding only 1.8% had BRCA mutations and 14.2% were classified as high risk.
  • Results showed high-risk patients had significantly worse 10-year overall survival rates compared to other patients, highlighting the need for careful patient identification to ensure those who could benefit from olaparib receive appropriate care
View Article and Find Full Text PDF

The bromodomain adjacent to zinc finger 2B (BAZ2B) gene encodes a chromatin remodeling protein that has been shown to perform a variety of regulatory functions. It has been proposed that loss of BAZ2B function is associated with neurodevelopmental phenotypes, and some recurrent structural birth defects and dysmorphic features have been documented among individuals carrying heterozygous loss-of-function BAZ2B variants. However, additional evidence is needed to confirm that these phenotypes are attributable to BAZ2B deficiency.

View Article and Find Full Text PDF

Introduction: With the emergence of targeted therapies, there is a need to accurately identify more tumor biomarkers. The EXOMA trial was designed to offer tumor and germline exome sequencing (ES) to patients with solid malignant tumors and facing therapeutic failure. As hereditary cancer predispositions could be identified, with genetic counseling and health management implications, a genetic consultation was systematically established.

View Article and Find Full Text PDF
Article Synopsis
  • The PIK3CA-related overgrowth spectrum (PROS) includes conditions caused by mosaic variants in the PIK3CA gene, which can also lead to various cancers, including an increased risk of Wilms tumor (WT).
  • A study of 267 PROS patients found a low overall cancer development rate of 2.2%, with an estimated 5.6% probability of cancer by age 45, suggesting the risk of WT in these patients is relatively low.
  • The findings indicate that routine abdominal ultrasound for cancer detection in PROS might not be necessary, and more long-term studies are needed to better understand the risks of different cancers and their connection to PIK3CA variants.
View Article and Find Full Text PDF

Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation sequencing (NGS), progress in biomedical technologies, and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells-such as homologous recombination deficiencies (HRD)-enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors.

View Article and Find Full Text PDF
Article Synopsis
  • Taxanes are effective drugs for treating metastatic breast cancer (MBC) and can be safely readministered, leading to questions about their reintroduction value in previously treated patients.
  • A study of 756 MBC patients found that 58 (7.8%) underwent taxane rechallenge, revealing that these patients were generally younger, had better health, and responded favorably to earlier treatments.
  • The rechallenge resulted in a 27.6% objective response rate and a median progression-free survival of 5.7 months, suggesting that taxane rechallenge is a viable treatment option for certain MBC patients.
View Article and Find Full Text PDF
Article Synopsis
  • * A study analyzed the impact of specific genes on treatment outcomes in 445 solid cancer patients, revealing that certain genetic variants can affect drug metabolism and clearance.
  • * The findings suggest that genetic testing can help tailor cancer treatments by predicting patients' responses to drugs, particularly in cases involving 5-fluorouracil and opioid therapies.
View Article and Find Full Text PDF

Background: Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical.

Objectives: This pharmacokinetic/pharmacodynamic (PK/PD) study was conducted to establish the effect of different G-CSF regimens on neutropenia's incidence for patients treated by eribulin, to propose an optimal G-CSF dosing schedule.

Methods: A population PK/PD model was developed to describe absolute neutrophil counts' (ANC) time course in 87 cancer patients receiving eribulin.

View Article and Find Full Text PDF

Background: Genomically-guided clinical trials are performed across different tumor types sharing genetic mutations, but trial organization remains complex. Here we address the feasibility and utility of routine somatic and constitutional exome analysis in metastatic cancer patients.

Methods: Exoma trial (NCT02840604) is a multicenter, prospective clinical trial.

View Article and Find Full Text PDF

KRAS (Kirsten rat sarcoma viral oncogene) or BRAF (v-raf murine sarcoma viral oncogene homolog B1) constitutive activation leads to anti-EGFR (epidermal growth factor receptor) therapy resistance of metastatic colorectal cancer patients. In this article we investigate the effects of anti-MEK (mitogen-activated protein kinase) antibody (trametinib) combined with anti-EGFR (cetuximab) on colon cancer cell lines with different RAS statuses. Even though cetuximab has no effect on RAS cell viability and ERK (extracellular-signal-regulated kinase) phosphorylation (one of the last kinases of the EGFR pathway), trametinib can induce cell death and inhibit the activation of ERK alone or in combination with cetuximab.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionnrr6j2aql6kqpudq71thsu719c889n9t): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once